Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celcuity Inc. stock logo
CELC
Celcuity
$12.11
-3.6%
$10.76
$7.58
$19.77
$458.56M0.37291,141 shs115,413 shs
Enhabit, Inc. stock logo
EHAB
Enhabit
$9.77
-2.0%
$9.21
$6.85
$10.91
$495.23M1.8462,484 shs400,689 shs
InnovAge Holding Corp. stock logo
INNV
InnovAge
$3.54
-4.1%
$3.47
$2.60
$6.69
$477.95M0.5552,854 shs30,779 shs
Exagen Inc. stock logo
XGN
Exagen
$7.12
+2.0%
$6.00
$1.71
$7.56
$151.66M1.6124,124 shs377,638 shs
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celcuity Inc. stock logo
CELC
Celcuity
0.00%-7.20%+15.11%+20.74%-19.27%
Enhabit, Inc. stock logo
EHAB
Enhabit
0.00%-9.50%-9.20%+13.94%+3.94%
InnovAge Holding Corp. stock logo
INNV
InnovAge
0.00%-11.94%-16.11%+9.94%-31.53%
Exagen Inc. stock logo
XGN
Exagen
0.00%-1.79%+24.04%+100.00%+261.42%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Celcuity Inc. stock logo
CELC
Celcuity
1.9071 of 5 stars
3.60.00.00.03.12.50.0
Enhabit, Inc. stock logo
EHAB
Enhabit
1.002 of 5 stars
1.03.00.00.01.60.02.5
InnovAge Holding Corp. stock logo
INNV
InnovAge
1.7766 of 5 stars
2.82.00.00.02.71.70.6
Exagen Inc. stock logo
XGN
Exagen
3.3767 of 5 stars
1.53.00.04.52.92.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Celcuity Inc. stock logo
CELC
Celcuity
3.17
Buy$30.80154.34% Upside
Enhabit, Inc. stock logo
EHAB
Enhabit
2.00
Hold$8.50-13.00% Downside
InnovAge Holding Corp. stock logo
INNV
InnovAge
1.50
Reduce$5.0041.24% Upside
Exagen Inc. stock logo
XGN
Exagen
3.00
Buy$7.505.34% Upside

Current Analyst Ratings Breakdown

Latest XGN, CELC, EHAB, and INNV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
Celcuity Inc. stock logo
CELC
Celcuity
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
5/15/2025
Exagen Inc. stock logo
XGN
Exagen
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
5/15/2025
Celcuity Inc. stock logo
CELC
Celcuity
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
5/15/2025
Exagen Inc. stock logo
XGN
Exagen
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$8.00 ➝ $7.00
5/13/2025
Exagen Inc. stock logo
XGN
Exagen
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $8.00
5/7/2025
Exagen Inc. stock logo
XGN
Exagen
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/11/2025
Celcuity Inc. stock logo
CELC
Celcuity
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
4/1/2025
Celcuity Inc. stock logo
CELC
Celcuity
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
4/1/2025
Celcuity Inc. stock logo
CELC
Celcuity
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Celcuity Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/A$5.48 per shareN/A
Enhabit, Inc. stock logo
EHAB
Enhabit
$1.03B0.48$3.01 per share3.25$13.90 per share0.70
InnovAge Holding Corp. stock logo
INNV
InnovAge
$831.68M0.57N/AN/A$1.90 per share1.86
Exagen Inc. stock logo
XGN
Exagen
$56.72M2.67N/AN/A$1.33 per share5.35
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Celcuity Inc. stock logo
CELC
Celcuity
-$63.78M-$3.03N/AN/AN/AN/A-62.66%-39.78%8/13/2025 (Estimated)
Enhabit, Inc. stock logo
EHAB
Enhabit
-$80.50M-$2.77N/A33.69N/A-11.24%1.67%0.80%8/5/2025 (Estimated)
InnovAge Holding Corp. stock logo
INNV
InnovAge
-$21.34M-$0.23N/A59.00N/A-3.19%-9.45%-4.84%N/A
Exagen Inc. stock logo
XGN
Exagen
-$23.69M-$0.84N/AN/AN/A-30.36%-92.58%-33.74%8/4/2025 (Estimated)

Latest XGN, CELC, EHAB, and INNV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Celcuity Inc. stock logo
CELC
Celcuity
-$0.95-$0.86+$0.09-$0.86N/AN/A
5/12/2025Q1 2025
Exagen Inc. stock logo
XGN
Exagen
-$0.20-$0.20N/A-$0.20$14.55 million$15.50 million
5/7/2025Q1 2025
Enhabit, Inc. stock logo
EHAB
Enhabit
$0.07$0.10+$0.03$0.35$266.11 million$259.90 million
5/6/2025Q3 2025
InnovAge Holding Corp. stock logo
INNV
InnovAge
-$0.02-$0.08-$0.06-$0.08$214.09 million$218.14 million
3/31/2025Q4 2024
Celcuity Inc. stock logo
CELC
Celcuity
-$0.72-$0.85-$0.13-$0.85N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Celcuity Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/AN/A
Enhabit, Inc. stock logo
EHAB
Enhabit
N/AN/AN/AN/AN/A
InnovAge Holding Corp. stock logo
INNV
InnovAge
N/AN/AN/AN/AN/A
Exagen Inc. stock logo
XGN
Exagen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Celcuity Inc. stock logo
CELC
Celcuity
0.65
10.35
10.36
Enhabit, Inc. stock logo
EHAB
Enhabit
0.85
1.46
1.46
InnovAge Holding Corp. stock logo
INNV
InnovAge
0.27
1.16
1.16
Exagen Inc. stock logo
XGN
Exagen
1.54
4.05
4.05

Institutional Ownership

CompanyInstitutional Ownership
Celcuity Inc. stock logo
CELC
Celcuity
63.33%
Enhabit, Inc. stock logo
EHAB
Enhabit
N/A
InnovAge Holding Corp. stock logo
INNV
InnovAge
12.26%
Exagen Inc. stock logo
XGN
Exagen
75.25%

Insider Ownership

CompanyInsider Ownership
Celcuity Inc. stock logo
CELC
Celcuity
15.77%
Enhabit, Inc. stock logo
EHAB
Enhabit
3.40%
InnovAge Holding Corp. stock logo
INNV
InnovAge
1.40%
Exagen Inc. stock logo
XGN
Exagen
12.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Celcuity Inc. stock logo
CELC
Celcuity
4037.87 million31.27 millionOptionable
Enhabit, Inc. stock logo
EHAB
Enhabit
10,90050.64 million49.33 millionOptionable
InnovAge Holding Corp. stock logo
INNV
InnovAge
2,000135.01 million133.35 millionOptionable
Exagen Inc. stock logo
XGN
Exagen
22021.30 million13.03 millionOptionable

Recent News About These Companies

Cantor Fitzgerald Weighs in on Exagen FY2026 Earnings
Exagen Inc. stock logo
Cantor Fitzgerald Estimates Exagen FY2026 Earnings
Exagen Inc. stock logo
Exagen Inc. (NASDAQ:XGN) Short Interest Update

New MarketBeat Followers Over Time

Media Sentiment Over Time

Celcuity stock logo

Celcuity NASDAQ:CELC

$12.11 -0.45 (-3.58%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$11.54 -0.57 (-4.75%)
As of 06/13/2025 06:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Enhabit stock logo

Enhabit NYSE:EHAB

$9.77 -0.20 (-2.01%)
Closing price 06/13/2025 03:59 PM Eastern
Extended Trading
$9.78 +0.02 (+0.15%)
As of 06/13/2025 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was founded in 1998 and is based in Dallas, Texas.

InnovAge stock logo

InnovAge NASDAQ:INNV

$3.54 -0.15 (-4.07%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$3.54 0.00 (0.00%)
As of 06/13/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. The company manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. It also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management. The company serves participants in the United States; and operates PACE centers in Colorado, California, New Mexico, Pennsylvania, Florida, and Virginia. The company was formerly known as TCO Group Holdings, Inc. and changed its name to InnovAge Holding Corp. in January 2021. InnovAge Holding Corp. was founded in 2007 and is headquartered in Denver, Colorado.

Exagen stock logo

Exagen NASDAQ:XGN

$7.12 +0.14 (+2.01%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$7.20 +0.09 (+1.19%)
As of 06/13/2025 06:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.